
Synaffix expands ADC deal from 2022 with MacroGenics
The Dutch biotech Synaffix, which has been active in the deal space out of the gate in 2023, is building on a deal it made with MacroGenics last year.
Synaffix announced Tuesday it has expanded an agreement with the biotech MacroGenics to license out its antibody conjugation platform, called GlycoConnect, along with other pieces of Synaffix’s technology. The deal is designed to create several ADC programs. Both companies inked the first in February 2022, which netted Synaffix $586 million in upfront and milestone payments, with three programs being developed. Synaffix is eligible for royalties on commercial sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.